Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
irinotecan liposomes
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
Irinotecan liposomes is a nanoparticle-encapsulated formulation of irinotecan, a cytotoxic small molecule that acts as a topoisomerase I inhibitor. This formulation is designed to enhance the therapeutic index of irinotecan by prolonging circulation time and increasing drug accumulation within the tumor microenvironment. Zhejiang Cancer Hospital is investigating this agent in a Phase I trial for locally advanced rectal cancer, where it is administered weekly in combination with capecitabine-based neoadjuvant chemoradiation. The treatment strategy utilizes UGT1A1 genotyping to guide dose escalation, aiming to optimize efficacy while minimizing the risk of dose-limiting toxicities such as neutropenia and diarrhea.
- Other names
- liposomal irinotecanirinotecan liposome
02
Targets
TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on irinotecan liposomes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on irinotecan liposomes.